NCT06920199View on ClinicalTrials.gov

Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 14, 2025

Primary Completion Date

May 15, 2027

Study Completion Date

September 15, 2027

Conditions
cGVHD
Interventions
BIOLOGICAL

Donor-derived Treg cell injection combined with interleukin 2

Subjects received Treg cell infusion at day D0, and interleukin 2 was administered subcutaneously daily from 1 week before to 12 weeks after infusion.

Trial Locations (1)

200080

RECRUITING

Shanghai General Hospital, Shanghai

All Listed Sponsors
lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER